Patient Diversity in MEA Trials: SAHPRA & Regulator Gap

Patient Diversity in MEA Clinical Trials: Strategies for Inclusive Recruitment

This article discusses the importance of patient diversity in MEA clinical trials and outlines strategies to enhance inclusive recruitment for better drug efficacy.

Dr. Priya Sharma MBBS, MSc Clinical Pharmacology · Asia Clinical Research Editor

Reviewed by Dr. Anil Kapoor Medical Oncologist, Medical Reviewer

Wednesday, April 29, 2026 13 min read Updated Jul 13, 2026

Quick Answer

This article discusses the importance of patient diversity in MEA clinical trials and outlines strategies to enhance inclusive recruitment for better drug efficacy.

Key Questions

Why does the MEA region lack clinical trial diversity data?
What FDA guidance applies to diversity in clinical trials?
How many African countries have ratified the African Medicines Agency treaty?
What barriers prevent MEA patient participation in clinical trials?
What strategies improve diversity in MEA clinical trials?

Patient diversity in MEA clinical trials remains largely unregulated compared to FDA standards. While the FDA mandates Diversity Action Plans under FDORA Section 3602, SAHPRA and other Middle East and Africa regulators have not issued comparable binding guidance. This gap leaves sponsors without clear demographic reporting requirements, potentially compromising trial generalizability across MEA's diverse populations.

Key Takeaways

Regulatory gap: SAHPRA issues clinical trial guidelines (SAHPGL-CEM-CT series) but lacks specific diversity mandates compared to FDA Diversity Action Plan requirements under FDORA Section 3602. Learn more in our SAHPRA expedited review analysis.
Capacity constraints: Per WHO Global Benchmarking Tool assessments, 34 of 47 assessed African countries operate at basic regulatory maturity (Level 1), lacking infrastructure for diversity tracking.
African Medicines Agency progress: The AU treaty for the African Medicines Agency was approved in February 2019; 14 of 20 signatory states have ratified it as of 2021.
Underrepresentation documented: A 2025 PubMed analysis confirms MENA region underrepresentation in oncology trials, with trial density varying by country. See our real-world evidence report for complementary data.
Strategic recommendations: Community engagement, decentralized trial models, and culturally adapted informed consent—aligned with FDA participation guidance—can improve MEA recruitment diversity.

Why Does Patient Diversity Matter for MEA Trials?

Patient diversity in clinical trials ensures results apply to the populations who will use approved therapies. The Middle East and Africa region has 54 African nations and 21 Middle Eastern countries. These populations show distinct genetic backgrounds, disease patterns, and healthcare access that may affect drug efficacy and safety.

Genetic differences vary across MEA populations. For example, pharmacogenomic differences affect drug metabolism for common cardiovascular and psychiatric medications. Without adequate representation in trial cohorts, regulatory approvals may not reflect how drugs perform in regional patients. This gap raises ethical concerns about research benefits and practical concerns about post-market safety.

Unlike the United States, where the FDA mandates Diversity Action Plans under FDORA Section 3602, MEA regulatory bodies have not established comparable requirements. SAHPRA's clinical trial guidelines focus on Good Clinical Practice (GCP) compliance and ethical conduct rather than demographic representation benchmarks.

What Is the Current Regulatory Framework?

South Africa's SAHPRA Framework

SAHPRA serves as the primary medicines regulator for South Africa and a reference authority for the Southern African Development Community. The agency maintains multiple clinical trial guidelines including:

Read more about clinical trial developments across MEA markets.

SAHPGL-CEM-CT-08: Capacity Building and Transformation (Version 2, updated October 2022)
SAHPGL-CEM-CT-09: Guidelines for Clinical Trial Investigators (Version 3)
SAHPGL-CEM-CT-02: Compensation Model for Participant Time, Inconvenience and Expense

These guidelines address ethical conduct, investigator responsibilities, and participant compensation. However, none specify mandatory demographic reporting or diversity targets for trial enrollment. SAHPRA does not publicly compile aggregate diversity statistics analogous to FDA's demographic reporting requirements.

Other MEA Regulatory Bodies

The Saudi Food and Drug Authority (SFDA) regulates trials in the Kingdom under Version 3.0 of its Clinical Trials Regulations, issued in July 2015 and periodically updated. Like SAHPRA, SFDA emphasizes GCP compliance without specific diversity mandates.

Individual Middle Eastern and African nations operate under distinct regulatory frameworks. This fragmentation creates complexity for sponsors seeking consistent diversity standards across multi-country trials. The African Vaccine Regulatory Forum (AVAREF) and WHO prequalification programs provide some harmonization, but diversity reporting remains voluntary.

African Medicines Agency Progress

The African Medicines Regulatory Harmonisation (AMRH) Initiative, formalized in 2009, aims to shift from country-focused to collaborative regional regulation. The AU treaty establishing the African Medicines Agency (AMA) was approved by the AU Heads of State Summit in February 2019.

As of 2021, per WHO regional committee reports, 20 African Union Member States have signed the AMA treaty and 14 have ratified it. The agency will require 15 ratifications to become fully operational. When active, the AMA could establish continent-wide diversity standards for clinical trials.

What Barriers Limit MEA Patient Participation?

Several barriers limit patient diversity in MEA clinical trials:

Barrier Category	Specific Challenges	Impact on Enrollment
Socio-economic	Transportation costs, lost wages, competing priorities	Skewed toward affluent participants
Cultural/Linguistic	Language diversity, health literacy variations	Consent comprehension gaps
Infrastructure	Limited trial sites, inconsistent EHR systems	Geographic access inequities
Regulatory	Fragmented national frameworks	Sponsor uncertainty on requirements
Historical	Legacy of research exploitation	Community mistrust

A 2025 PubMed analysis of MENA representation in oncology trials documented significant country-level variation in trial participation. The study found that trial density per million population varies substantially across Middle Eastern and North African countries, indicating unequal access to clinical research opportunities.

Similarly, research on global heart failure trials published in 2025 identified a "formidable mismatch" between disease epidemiology and trial enrollment, with African and Middle Eastern populations underrepresented in pivotal cardiovascular trials despite high regional disease burden.

How Can Sponsors Improve Diversity in MEA Trials?

Trial sponsors can employ evidence-based strategies adapted to regional contexts:

Community engagement: Partner with local patient advocacy groups and community health workers during trial design. This approach identifies cultural sensitivities and communication preferences that centralized strategies miss.
Culturally adapted informed consent: Translate documents into local languages and simplify for regional health literacy levels. Video-based consent tools and in-person explanations by trained local staff enhance comprehension, per FDA participation guidance.
Decentralized trial models: Enable enrollment at community health centers and telemedicine visits to reduce transportation barriers. Hybrid models work effectively in regions with dispersed populations.
Capacity building: Invest in training for local healthcare providers and research coordinators on culturally competent recruitment and SAHPRA GCP requirements.
Participant support services: Provide transportation assistance and modest compensation calibrated to regional income levels, following SAHPRA's TIE (Time, Inconvenience, Expense) compensation model.
Transparent enrollment tracking: Establish baseline demographic targets and monitor real-time enrollment by age, sex, and geographic region. Implement corrective measures when targets are not met.

What Regulatory Changes Could Improve Diversity?

SAHPRA and other MEA regulatory bodies could strengthen diversity through several mechanisms:

First, issue formal guidance specifying demographic reporting requirements and diversity benchmarks. This guidance could align with FDA Diversity Action Plan standards while accommodating regional capacity constraints.

Second, require sponsors to justify demographic imbalances in trial cohorts. Applications could include diversity enrollment plans with specific targets for underrepresented groups.

Third, harmonize diversity frameworks across MEA regulators. The African Medicines Agency could establish continent-wide standards once operational. Similarly, Gulf Cooperation Council health ministers could align SFDA and other national requirements.

Fourth, invest in regulatory capacity. Per WHO assessments, advancing national regulatory authorities from basic maturity levels requires sustained funding, training, and infrastructure development.

Frequently Asked Questions

Why does the MEA region lack clinical trial diversity data?

The Middle East and Africa region lacks systematic diversity data because SAHPRA and other national regulatory authorities have not issued binding guidance mandating demographic reporting, unlike the FDA's Diversity Action Plan requirements under FDORA Section 3602. Additionally, 34 of 47 African countries assessed by WHO in 2020 still operate at basic regulatory maturity levels without capacity for diversity tracking.

What FDA guidance applies to diversity in clinical trials?

The FDA issued final guidance in 2024 on Diversity Action Plans under FDORA Section 3602, requiring sponsors to submit plans for enrolling participants from underrepresented populations. The FDA also maintains guidance on Enhancing Participation in Clinical Trials (Docket FDA-2019-D-1264) covering demographic characteristics including race, ethnicity, age, and geographic location.

How many African countries have ratified the African Medicines Agency treaty?

As of 2021, 14 African Union Member States have ratified the African Medicines Agency (AMA) treaty, which was approved by the AU Heads of State Summit in February 2019. Twenty states have signed the treaty, but full operationalization requires 15 ratifications.

What barriers prevent MEA patient participation in clinical trials?

Key barriers include: 1) Socio-economic constraints including transportation costs and competing priorities; 2) Cultural and linguistic factors requiring adapted consent materials; 3) Infrastructure gaps with limited trial site networks; 4) Regulatory fragmentation across 54 African and 21 Middle Eastern countries; and 5) Low health literacy requiring video-based and in-person consent explanations.

What strategies improve diversity in MEA clinical trials?

Effective strategies include community engagement with local patient advocacy groups, culturally adapted informed consent in local languages, decentralized trial models reducing transportation barriers, capacity building for local research staff per SAHPRA guidelines, and transparent demographic enrollment tracking with real-time monitoring.

Primary Sources

U.S. Food and Drug Administration. Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. Docket Number: FDA-2021-D-0789. Final guidance issued under FDORA Section 3602. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies
U.S. Food and Drug Administration. Enhancing Participation in Clinical Trials — Eligibility Criteria, Enrollment Practices, and Trial Designs. Docket Number: FDA-2019-D-1264. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-participation-clinical-trials-eligibility-criteria-enrollment-practices-and-trial-designs
South African Health Products Regulatory Authority (SAHPRA). Clinical Trials Guidelines. Multiple documents including SAHPGL-CEM-CT-08 (v2, October 2022). https://www.sahpra.org.za/clinical-trials-guidelines/
Saudi Food and Drug Authority (SFDA). Regulations and Requirements for Conducting Clinical Trials on Drugs. Version 3.0, issued July 2015; updated January 2025. https://www.sfda.gov.sa/sites/default/files/2025-01/ConductingClinicalTrialsDrugE.pdf
World Health Organization Regional Committee for Africa. Progress Report on the Implementation of the Regional Strategy on Regulation of Medical Products in the African Region, 2016–2025. Document AFR/RC71/INF.DOC/5, July 2021. https://iris.who.int/bitstreams/3f67caac-9085-4930-bf80-6b0eeb84af41/download
Ndomondo-Sigonda M, et al. The African Medicines Regulatory Harmonization Initiative & African Medicines Agency. WHO-UNICEF-UNFPA Joint Meeting Presentation, November 2022. https://extranet.who.int/prequal/sites/default/files/document_files/Day-1_Session-4.4_MargaretSigonda_AMRH_AMA.pdf
Meirson T, et al. Representation of the Middle East and North African Region in Oncology Clinical Trials. PubMed PMID: 40272821. Published June 2025. https://pubmed.ncbi.nlm.nih.gov/40272821/
Baudry G, et al. Global heart failure epidemiology versus enrolment in pivotal trials: A formidable mismatch. European Journal of Heart Failure. PubMed PMID: 40436420. Published 2025. https://pubmed.ncbi.nlm.nih.gov/40436420/
African Union. Regional Strategy on Regulation of Medical Products in the African Region, 2016–2025. Resolution AFR/RC66/R2. https://www.afro.who.int/sites/default/files/sessions/resolutions/afr-rc66-r2-en-2109.pdf
World Health Organization. Global Benchmarking Tool for Evaluation of National Regulatory Systems. Accessed via WHO medicines regulation portal. https://www.who.int/medicines/regulation/benchmarking_tool/en/